$4.49 Billion is the total value of Cormorant Asset Management, LP's 120 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 28.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Sell | SPDR SER TRput | $135,650,000 | -35.8% | 1,000,000 | -33.3% | 3.02% | -39.9% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $133,605,000 | -17.1% | 2,168,909 | -4.3% | 2.98% | -22.4% |
| BCAB | Sell | BIOATLA INC | $109,927,000 | +45.8% | 2,192,060 | -4.4% | 2.45% | +36.4% |
| OMER | Sell | OMEROS CORP | $58,741,000 | +2.8% | 3,300,030 | -17.5% | 1.31% | -3.8% |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $53,752,000 | -14.5% | 2,464,545 | -0.0% | 1.20% | -20.0% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $47,108,000 | -34.0% | 275,000 | -15.4% | 1.05% | -38.3% |
| CCXI | Sell | CHEMOCENTRYX INC | $43,554,000 | -41.4% | 850,000 | -29.2% | 0.97% | -45.1% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $39,880,000 | -35.5% | 400,000 | -20.0% | 0.89% | -39.6% |
| IGMS | Sell | IGM BIOSCIENCES INC | $38,021,000 | -28.2% | 495,769 | -17.4% | 0.85% | -32.8% |
| XLRN | Sell | ACCELERON PHARMA INC | $37,293,000 | -31.4% | 275,000 | -35.3% | 0.83% | -35.8% |
| YMAB | Sell | Y-MABS THERAPEUTICS INC | $37,195,000 | -54.8% | 1,230,000 | -26.0% | 0.83% | -57.7% |
| TWST | Sell | TWIST BIOSCIENCE CORP | $22,914,000 | -27.9% | 185,000 | -17.8% | 0.51% | -32.6% |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $22,742,000 | -26.0% | 2,750,000 | -38.9% | 0.51% | -30.6% |
| MYOV | Sell | MYOVANT SCIENCES LTD | $20,580,000 | -56.2% | 1,000,000 | -41.2% | 0.46% | -59.0% |
| ZLAB | Sell | ZAI LAB LTDadr | $20,014,000 | -21.8% | 150,000 | -20.7% | 0.45% | -26.8% |
| INSP | Sell | INSPIRE MED SYS INC | $17,594,000 | -6.5% | 85,000 | -15.0% | 0.39% | -12.5% |
| BEAM | Sell | BEAM THERAPEUTICS INC | $13,749,000 | -81.8% | 171,775 | -81.4% | 0.31% | -83.0% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $13,670,000 | -62.5% | 200,000 | -52.9% | 0.30% | -64.8% |
| BNTX | Sell | BIONTECH SEsponsored ads | $10,919,000 | -51.3% | 100,000 | -63.6% | 0.24% | -54.4% |
| AKUS | Sell | AKOUOS INC | $6,935,000 | -30.1% | 499,989 | -0.0% | 0.15% | -34.7% |
| GTH | Sell | GENETRON HLDGS LTDads | $6,438,000 | +15.0% | 300,000 | -25.0% | 0.14% | +7.5% |
| IMVT | Sell | IMMUNOVANT INC | $5,406,000 | -92.5% | 337,048 | -78.4% | 0.12% | -93.0% |
| KDMN | Sell | KADMON HLDGS INC | $2,918,000 | -17.3% | 750,000 | -11.8% | 0.06% | -22.6% |
| ALLK | Sell | ALLAKOS INC | $2,870,000 | -59.0% | 25,000 | -50.0% | 0.06% | -61.7% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $400,000 | -41.2% | 20,000 | -50.0% | 0.01% | -43.8% |
| MGEN | Exit | MIRAGEN THERAPEUTICS INC | $0 | – | -93,126 | -100.0% | -0.04% | – |
| PANAU | Exit | PANACEA ACQUISITION CORPunit 99/99/9999 | $0 | – | -250,000 | -100.0% | -0.08% | – |
| AVRO | Exit | AVROBIO INC | $0 | – | -244,032 | -100.0% | -0.08% | – |
| FSDC | Exit | FS DEV CORP | $0 | – | -500,000 | -100.0% | -0.13% | – |
| OTIC | Exit | OTONOMY INC | $0 | – | -2,600,000 | -100.0% | -0.40% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -650,000 | -100.0% | -0.50% | – |
| NVUS | Exit | NOVUS THERAPEUTICS INC | $0 | – | -1,415,500 | -100.0% | -0.51% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -200,000 | -100.0% | -0.73% | – |
| VIE | Exit | VIELA BIO INC | $0 | – | -1,429,200 | -100.0% | -1.22% | – |
| QQQ | Exit | INVESCO QQQ TRput | $0 | – | -750,000 | -100.0% | -5.60% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.